Filing summary
Entity mismatch: The supplied filing is for Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended March 31, 2012, filed May 3, 2012. The summary below reflects the filing text provided.
Business context and reporting period
Synta was a clinical-stage biopharmaceutical company developing treatments for cancer and inflammatory diseases. It reported no product sales and relied on financing, grants, and former collaboration arrangements. Its lead clinical program was ganetespib; other programs included elesclomol, STA-9584, and CRACM and IL-12/23 inhibitors. The interim financial statements are unaudited.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 or comparison |
|---|---|---|
| Revenue | $0.147 million | $1.143 million; down 91% |
| Research and development expense | $12.066 million | $9.436 million; up 29% |
| General and administrative expense | $2.646 million | $2.673 million |
| Operating loss | $14.565 million | $10.966 million |
| Net loss | $15.051 million | $11.401 million |
| Net loss per share | $0.27 | $0.27 |
| Operating cash used | $15.254 million | $12.839 million |
| Cash, cash equivalents and marketable securities | $57.4 million at March 31, 2012 | $39.7 million at December 31, 2011 |
| Working capital | $42.4 million | $23.4 million at March 31, 2011 |
| Total term loans | $16.471 million principal outstanding | Scheduled maturities: $4.083 million in 2012, $7.924 million in 2013, and $4.464 million in 2014 |
Revenue was entirely grant revenue in Q1 2012; the prior-year quarter included $1.143 million of Roche collaboration revenue. The company recorded a comprehensive loss of $15.035 million in Q1 2012. No meaningful product gross margin was reported because there were no product sales. Net cash provided by financing was $33.050 million, principally reflecting the public offering; investing activities used $13.321 million, including purchases of marketable securities.
Material changes and unusual items
- In January and February 2012, Synta sold 8.05 million shares at $4.40 per share, raising approximately $35.4 million gross and $33.0 million net. A director and largest stockholder bought 1,136,363 shares.
- Roche’s collaboration terminated effective February 16, 2012. Rights to the covered compounds reverted to Synta, which may owe low-single-digit royalties on future sales. Synta reported no termination costs or penalties.
- R&D spending rose primarily because of ganetespib clinical-trial activity and trial start-up costs. The company said lower CRACM spending after the Roche termination partly offset higher ganetespib investment.
- After quarter-end, the Azimuth equity line expired May 1 without any shares sold. On May 2, Synta entered an optional at-the-market facility for up to $35 million, with commissions of up to 3%; no shares had been sold as of the filing.
Outlook, commentary and risks
- Management expected cash resources to fund operations into the first half of 2013, based on then-current operating plans. It cautioned that additional trials or activities could require funding sooner.
- Management anticipated higher 2012 ganetespib costs, while G&A was expected to remain near 2011 levels. It did not expect product revenue in the foreseeable future and anticipated continued operating losses and cash use.
- Preliminary GALAXY trial results were expected in Q2 2012; additional GALAXY results and preliminary results from ALK-positive lung cancer and breast cancer trials were expected in the second half of 2012. These are management expectations, not reported outcomes.
- Key risks include clinical efficacy and safety uncertainty, trial timing and cost, regulatory requirements, inability to secure collaborations or financing on acceptable terms, potential shareholder dilution, and possible need to delay or reduce development programs. The filing stated there were no material changes to previously disclosed risk factors.
- The GECC loan carried 9.75% annual interest, with interest-only payments through June 2012 followed by principal and interest payments; the Oxford loan carried 13.35% interest. The GECC loan was secured by substantially all assets except intellectual property, subject to a springing IP lien under specified covenant conditions.
Important facts for investors to verify
- Confirm the issuer: the filing is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Review subsequent clinical-trial results and whether the stated 2012 milestones were achieved.
- Assess cash burn, available liquidity, debt repayment obligations, and the assumptions behind the first-half-2013 runway estimate.
- Check any later use of the $35 million at-the-market facility and resulting dilution.
- Evaluate the consequences of Roche’s termination, including development plans for returned compounds and any future royalty obligations.